You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CTLA4

Showing 1 - 25 of 900
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CTLA4 Haploinsufficency, Chronic Cytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • CTLA4 Haploinsufficency
  • Chronic Cytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • SBRT, Fruquintinib, Cadonilimab
  • Wuhan, Hubei, China
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Health Volunteer Trial in Beijing (Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC

Recruiting
  • Health Volunteer
  • Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
  • +9 more
  • Beijing, China
    Peking University People's Hospital
Feb 15, 2022

Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland

Not yet recruiting
  • Locally Advanced Thyroid Gland Anaplastic Carcinoma
  • +2 more
  • Chicago, Illinois
  • +1 more
Jul 7, 2022

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Atlanta

Not yet recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +2 more
  • Atlanta, Georgia
  • +1 more
Feb 8, 2023

CTLA-4 and LRBA Hereditary Deficiency

Completed
  • CTLA4 Haploinsufficiency
    • Montpellier, France
      Uhmontpellier
    Nov 12, 2021

    Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Oct 17, 2022

    Leptomeningeal Metastasis, NSCLC Stage IV, Melanoma Stage IV Trial in Geneva, St Gallen, Zurich (intrathecal nivolumab and

    Recruiting
    • Leptomeningeal Metastasis
    • +2 more
    • intrathecal nivolumab and intrathecal ipilimumab
    • Geneva, Switzerland
    • +2 more
    Dec 18, 2022

    Metastatic Soft-tissue Sarcoma Trial in United States (Cabozantinib, Nivolumab, Ipilimumab)

    Recruiting
    • Metastatic Soft-tissue Sarcoma
    • Stanford, California
    • +3 more
    Jan 10, 2023

    Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • AK104 lenvatinib
    • AK104
    • Hangzhou, Zhejiang, China
      The first affilited hospital zhejiang university school of medci
    Oct 17, 2022

    Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Brussels, Barcelona, Madrid (JK08)

    Recruiting
    • Cancer
    • +6 more
    • Brussels, Belgium
    • +3 more
    Jan 30, 2023

    NSCLC (Non-small-cell Lung Cancer) Trial in Changchun (Sintilimab, IBI310)

    Recruiting
    • NSCLC (Non-small-cell Lung Cancer)
    • Changchun, Jilin, China
      The First Hospital of Jilin University
    Sep 21, 2022

    Cadonilimab in Recurrent or Metastatic Cervical Cancer

    Not yet recruiting
    • Recurrent or Metastatic Cervical Cancer
    • (no location specified)
    Nov 23, 2023

    Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15

    Recruiting
    • Squamous Cell Carcinoma of the Head and Neck
    • Recurrent Head and Neck Squamous Cell Carcinoma
    • Interleukin-15 Superagonist (N-803)
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Dec 2, 2022

    Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

    Not yet recruiting
    • Cervical Cancer
    • Anti-PD-1 antibody balstilimab
    • Amsterdam, Netherlands
      Amsterdam UMC
    Oct 17, 2023

    Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, Tremelimumab (Cohort A

    Recruiting
    • Intermediate Stage of Hepatocellular Carcinoma
    • Hepatocellular Carcinoma
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center
    Oct 6, 2022

    Novel Genetic Disorders of the Immune System

    Recruiting
    • PI3KCD
    • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 2, 2023

      Sarcoma, Soft Tissue Trial in Changsha (Cardunilizumab)

      Active, not recruiting
      • Sarcoma, Soft Tissue
      • Changsha, Hunan, China
        Xiangya Hospital Central South University
      Oct 29, 2023

      Solid Tumor Trial in China (SI-B003)

      Recruiting
      • Solid Tumor
      • Beijing, Beijing, China
      • +7 more
      Jan 11, 2023

      Type 1 Diabetes, Diabetes, Type 1 Trial in Australia (Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept (CTLA4-Ig)

      Recruiting
      • Type 1 Diabetes
      • Diabetes Mellitus, Type 1
      • Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
      • Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)
      • Westmead, New South Wales, Australia
      • +5 more
      Feb 15, 2023

      SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

      Not yet recruiting
      • SCLC,Extensive Stage
      • AK104 IV infusion；Chiauranib oral
      • Changchun, Jilin, China
        Jilin Province Cancer Hospital
      Aug 16, 2022

      Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)

      Not yet recruiting
      • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
      • (no location specified)
      Feb 8, 2023